Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Signs Deal with Sequitir for Antisense Compounds

NEW YORK, Jan 29 – Sequitir said Monday it signed a multi-year, multi-million dollar deal to supply Bristol-Myers Squibb with its antisense compounds for target validation and to perform biological screening for the pharmaceutical company.

" We are excited to begin a large scale agreement with Bristol-Myers Squibb based on the successful completion of an agreement last year,” Tod Woolf, Sequitur's vice president of technology development, said in a statement. “We are particularly excited by the high throughput phenotypic target validation screening to be performed with Bristol-Myers Squibb.”

Woolf said the deal would result in the development of more than 1,000 antisense compounds that would be added to the company’s OmniScreen library.

Financial terms of the deal were not disclosed.

Sequitur's technology is used to discover and validate genes. Antisense inhibits gene expression, allowing researchers to better understand gene function and validate small molecule drug targets.

Privately held Sequitur of Natick, Mass., generally receives upfront licensing and milestone fees. In addition to OmniScreen, the company also offers GeneLink, a pathway elucidation technology.

Sequitir’s customers include Incyte Genomics, Amgen, and AstraZeneca.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.